INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Hamilton James C sold ARWR

Chief Medical Officer · ARROWHEAD PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$750K
Shares
10.0K
Price
$75
Executed
Apr 23, 2026
Disclosed
Apr 24, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Apr 23 executedApr 24, 2026 disclosed

ARWR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
11/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+7 / 25

    $750K reported value · 4.2% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ARWR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CG
    Cohen Matthew GregoryDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    11.9K sh
    		Jun 15, 2026Jun 17, 2026
    traded Jun 15, 2026
    		+2dSEC FORM 4

    Evidence

    21
    AJ
    Apel Daniel JosephChief Financial Officer
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    75.0K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    17
    HC
    Hamilton James CChief Medical Officer
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    75.0K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    12
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$186K
    2,799 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    15
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$359K
    5,281 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    12
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$134K
    1,960 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    17
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    7,819 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    13
    LH
    Lu HongboDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    7,819 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001830755-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 23, 2026
    Published
    Apr 24, 2026
    Ingested by INSIDER
    Nov 5, 04:02 UTC
    Last re-read
    Nov 5, 04:02 UTC

    Extracted facts

    Filer
    Hamilton James C
    Role
    Chief Medical Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    ARROWHEAD PHARMACEUTICALS, INC.
    Ticker
    ARWR
    Shares
    10.0K
    Price per share
    $75
    Value
    $750,000
    Execution date (reported)
    Apr 23, 2026
    Owned after transaction
    227.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 10.0K
    • Price: $75

    = $750,000

    What this establishes

    Hamilton James C filed this Form 4 reporting a open-market sale of ARWR on Apr 23, 2026. It became public on Apr 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Hamilton James Ccik:0001830755
    Issuer
    ARROWHEAD PHARMACEUTICALS, INC.cik:0000879407

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.